12.05.2019

AAKASHAYA PATRA EXCLUSIVE STOCK FOR INVESTMENT:

Jagsonpal Pharma (CMP Rs. 26.6)
Target -  52- 55, SL - 18 Time Frame 18 to 60 Months

Incorporated in 1964, Delhi based Jagsonpal Pharmaceuticals Limited develops and manufactures active pharmaceutical ingredients (APIs) and formulations. Its APIs include allylestrenol, dextropropoxyphene HCL, dextropropoxyphene
napsylate, disulfiram, thiopental sodium, thiopental acid, tolnaftate, and sildenafil citrate, as well as metformin HCL, BP, USP, and EP. The company also offers formulations for various therapeutic categories, such as anabolic steroids, analgesics, anesthetics, anti-allergic, anti-asthamatics, anticholinergic agents, anti-convulsants, anti-diabetics, anti-diarrhoeals, antiemetics,anti-epileptics, anti-fungal agents, anti-gout agents, anti-inflammatory agents, anti-malarials, anti-nauseants, anti-protozoals, anti-pyretic, antirheumatic drugs, anti-spasmodic agents, and anti-septic agents. The company
sells its products under the Lycored, Maintane, Metadec, Metabol,Doxypal DR, Parvon, and Indocap SR brand names through agents worldwide.It has an equity base of just Rs.13.10 crore that is supported by huge reserve of around Rs.77.11 crore. The promoters hold 70.26% while the investing public holds 29.74% stake in the company. Promoters increased
their stake by 1.09% between July-March 2019. JPL's share book value works out to Rs.34.43. Its P/BV ratio stands at just 0.75x.For 9MFY19, it posted profit after tax (PAT) of Rs.4.24 crore against loss of Rs.10.28 crore in 9MFY18 on 36.71% higher sales of Rs.128.42 crore fetching an EPS of Rs.1.62. Currently, the stock trades at 24% discount to its 52-week
high of Rs.34.95 recorded in September 2018.

Comments

Popular posts from this blog

AAKASHAYA PATRA SEVEN STAR SMART EDUCATION SERIES PART – 61 : 10.10.2020

AAKASHAYA PATRA EXCLUSIVE STOCK FOR INVESTMENT: 21.06.2020